Search Cancer Clinical Trials

The Cancer Center offers patients access to a wide variety of clinical trials of promising new therapies. Use the search tool to find open protocols for your type of cancer.
14 results
  • Lymphoma, Melanoma, Lung Cancer, Kidney Cancer, Bladder Cancer

21-481          Phase I

A First-in-Human, Multicenter, Open-Label, Phase 1 Dose-Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TAB004 as Monotherapy and in Combination with Toripalimab in Subjects with Advanced Solid Malignancies including Lymphoma (View details on

  • Bladder Cancer, Lung Cancer, Head and Neck Cancer, Melanoma

18-418          Phase III

A Multicenter, Open label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial. (View details on

  • Bladder Cancer

20-531          Phase II

A Multicenter, Single-Arm Open Label Phase II Trial of Cryoablation in Combination with Pembrolizumab in Patients with Metastatic Urothelial Carcinoma (View details on

  • Melanoma, Metastatic/Advanced Cancer, Head and Neck Cancer, Lung Cancer, Bladder Cancer

17-330          Phase I

A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors (View details on

  • Pancreatic Cancer, Sarcoma, Endometrial Cancer, Esophageal Cancer, Gastric (Stomach) Cancer, Liver Cancer, Bladder Cancer

20-544          Phase II

A Phase 1/2 Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PC14586 in Patients with Advanced Solid Tumors Harboring a p53 Y220C Mutation (View details on

  • Bladder Cancer, Lung Cancer, Head and Neck Cancer, Ovarian Cancer, Melanoma, Kidney Cancer, Breast Cancer

21-329          Phase II

A Phase 1a Open-Label, Dose-Escalation, and a Phase 2 Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of ST-067 Administered Subcutaneously as Monotherapy in Patients with Relapsed or Refractory Solid Tumors (View details on

  • Breast Cancer, Cervical Cancer, Uterine Cancer, Lung Cancer, Gallbladder and Bile Duct Cancers, Bladder Cancer

21-043          Phase II

A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated, Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations (View details on

  • Melanoma, Pancreatic Cancer, Bladder Cancer, Breast Cancer, Cervical Cancer, Chordoma, Ovarian Cancer, Endometrial Cancer, Esophageal Cancer, Lung Cancer

20-650          Phase II

A Phase II, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd) for the Treatment of Unresectable and/or Metastatic Solid Tumors Harboring HER2 Activating Mutations Regardless of Tumor Histology (View details on

  • Head and Neck Cancer, Bladder Cancer, Lymphoma, Lung Cancer

19-500          Phase I

An Open-Label, Multicenter, First-in-Human, Dose-Escalation, Phase 1 Study of INBRX-105 in Patients with Locally Advanced or Metastatic Solid Tumors, Hodgkin or Non-Hodgkin Lymphoma (View details on

Showing 1 - 10 of 14 results